BCTX BCTX
Company Profile ↓Company Overview
BCTX (BCTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -53.95% |
| 6 Months: | -19.17% |
| 3 Months: | -14.00% |
| 1 Month: | +0.29% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 74.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Oct 2021 | Jan 2022 | Apr 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Oct 2024 | Jan 2025 | Apr 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.28M | -3.65M | -4.12M | -5.40M | -4.49M | -5.68M | -8.50M | -9.83M | -9.23M | -5.15M | -7.17M | -6.33M | -8.32M | -7.53M | -7.62M |
| Net Income | -27.53M | 11.16M | -10.02M | -1.11M | -11.88M | -4.90M | 6.00M | -11.29M | 1.72M | -5.80M | -6.29M | -6.13M | -8.20M | -7.22M | -7.16M |
| Diluted EPS | - | 0.04 | -0.65 | -0.07 | -0.77 | -0.32 | -0.50 | -10.64 | 1.61 | -32.67 | -23.31 | -16.42 | -4.35 | -2.58 | -0.99 |
| R&D Expense | 875.64K | 1.71M | 2.27M | 3.26M | 3.05M | 3.86M | 6.86M | 8.26M | 7.66M | 3.67M | 5.68M | 4.81M | 6.68M | 6.05M | 5.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|
| Operating Income | -6.98M | -15.29M | -23.27M | -33.33M | -27.20M |
| Net Income | -13.82M | -26.84M | -20.30M | -4.79M | -26.31M |
| Diluted EPS | - | -1.73 | -1.30 | -43.68 | -62.19 |
| R&D Expense | 2.02M | 8.02M | 15.34M | 27.18M | 21.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 58.04M | 42.58M | 27.16M | 5.87M | 21.65M |
| Total Equity | -2.74M | 27.67M | 10.33M | -3.78M | -2.68M | 17.33M |
| Cash & Equivalents | - | 57.27M | 41.04M | 21.25M | 862.09K | 10.49M |
| Current Liabilities | - | 556.79K | 941.09K | 1.80M | 7.46M | 3.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -7.75M | -12.48M | -23.74M | -24.13M | -28.17M |
| Investing Cash Flow | - | - | - | -681.80K | -7.65M |
| Financing Cash Flow | 65.00M | -3.74M | 3.95M | 4.42M | 45.45M |
| Capital Expenditure | - | - | - | -456.80K | - |
| Free Cash Flow | - | - | - | -24.58M | - |
Ratios (Annual)
Figures in %.
| Metric | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | -49.9% | -259.8% | 537.5% | 178.5% | -151.8% |
| ROCE % | -12.1% | -36.7% | -91.8% | 2,097.7% | -153.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BCTX
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized immunotherapy for prostate cancer and i…
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?
In July 2026, BriaCell Therapeutics Corp. announced it had engaged Charles River Associates (CRA International) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand planning for Bria-IMT, its investigational …
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of “Eleven clin…
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell’s ongoing piv…
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solu…
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell’s pivotal Phase 3 study and is designed to support fas…
BCTX — Frequently Asked Questions
What is the current share price of BCTX?
As of 2026-08-05 17:25 PDT, BCTX trades at $3.50 on NASDAQ/NYSE. Its 52-week range is $2.74 to $13.79.
What is the P/E ratio of BCTX?
BCTX trades at a trailing price-to-earnings (P/E) ratio of -0.06.
Is BCTX a good stock to buy?
This page provides a data-driven analysis of BCTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.